Therapeutic strategies for depression;Stratégies thérapeutiques de la dépression

Therapie

Volumn 60, Issue 5, 2005, Pages 491-498

  Olie, Jean Pierre ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Antidepressant; Efficacy; Predictive criteria; Side effects

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DEXAMETHASONE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; INDALPINE; LIOTHYRONINE; LITHIUM; MAPROTILINE; MIRTAZAPINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL PROTOCOL; COMORBIDITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; ELECTROCONVULSIVE THERAPY; ELECTROSTIMULATION THERAPY; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; HUMAN; MAJOR DEPRESSION; NEUROENDOCRINE SYSTEM; NEUROIMAGING; OBSESSIVE COMPULSIVE DISORDER; PERSONALITY DISORDER; PHOBIA; PHYSICIAN; POLYSOMNOGRAPHY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; CLASSIFICATION; DEPRESSION;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DEPRESSIVE DISORDER; HUMANS;

EID: 33645212872     PISSN: 00405957     EISSN: 00405957     Source Type: Journal    
DOI: 10.2515/therapie:2005070     Document Type: Article

References (24)

1. Kaplan HI, Sadock BJ. Synopsie de psychiatrie. Paris: Editions Pradel, 1998: 1332-40
2. Preskorn SH, Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry 1992; 53 Suppl.: 5-18
3. Lefur G. A propos du mécanisme d'action supposé des antidépresseurs. Encephale 1980; 6: 303-13
4. Teneback CC, Nahas Z, Speer AM, et al. Changes in prefrontal cortex and paralimbic activity following two weeks of daily left prefrontal TMS. J Psychiatry Clin Neurosci 1999; 11: 426-35
5. Raskin A, Crook TA. The endogenous-neurotic distinction as a predictor of response to antidepressant drugs. Psychol Med 1976; 6: 59-70
6. Joyce PR, Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry 1989; 46: 89-99
7. Nagayama H, Nagano K, Ikekasi A, et al. Prediction of efficacy of antidepressant by 1 week test therapy in depression. J Affect Disord 1991; 23: 213-6
8. Quitkin FM, Stewart JW, McGrath PJ, et al. Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 1993; 150: 566-70
9. Khan A, Dager SR, Cohen S, et al. Chromcity of depressive episode in relation to antidepressant placebo response. Neuropsychopharmacology 1991; 4: 125-30
10. Corruble E, Duret C, Pelissolo A, et al. Early and delayed personality changes associated with depression recovery? A one-year follow-up study. Psychiatry Res 2002; 109: 17-25
11. Bielsky RJ, Friedel RO. Prediction of tricyclic antidepressant response. Arch Gen Psychiatry 1976; 33: 1479-89
12. Hayden EP, Klein DN. Outcome of dysthymic disorder at 5-year follow-up: the effect of familial psychopathology, early adversity, personality, comorbidity and chronic stress. Am J Psychiatry 2001; 158: 1864-70
13. Murphy E. The prognosis of depression in old age. Br J Psychiatry 1983; 142: 111-9
14. Meyer B, Pilkonis PA, Krupnick JL, et al. Treatment expectancies, patient alliance, and outcome: further analyses from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 2002; 70: 1051-5
15. Loo H, Benkelfat C, Poirier MF, et al. Plasma 3,4- dihydroxylphenylethyleneglycol and therapeutic response to maprotiline and indalpine in major depression. Neuropsychobiology 1986; 15: 62-7
16. Zobel AW, Nickel T, Sonntag A, et al. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. J Psychiatr Res 2001; 35: 83-94
17. Vanelle JM, Poirier MF, Benkelfat C, et al. Diagnostic and therapeutic value of testing stimulation of thyroid-stimulating hormone by thyrotropin-releasing hormone in 100 depressed patients. Acta Psychiatr Scand 1990; 81: 156-61
18. Bresnahan DB, Pandey GN, Janicak PG, et al. MAO inhibition and clinical response in depressed patients treated with phenelzine. J Clin Psychiatry 1990; 51: 47-50
19. Luthringer R, Minot R, Toussaint M, et al. All-night EEG spectral analysis as a tool for the prediction of clinical response to antidepressant treatment. Biol Psychiatry 1995; 38: 98-104
20. Thase ME, Kupfer DJ. Current status of EEG sleep in the assessment and treatment of depression. In: Burrow GD, Wery JS, editors. Advances in psychopharmacology. London: JAI Press, 1987: 4
21. Nadeau SE, McCoy KJ, Crucien GP, et al. Cerebral blood flow changes in depressed patients after treatment with repetitive transcranial magnetic stimulation: evidence of interindividual variability. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15: 159-75
22. Grunhaus L. Clinical and psychobiological characteristics of simultaneous panic disorder and major depression. Am J Psychiatry 1988; 145: 1214-21
23. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48: 730-8
24. Januel D, Massot O, Poirier MF, et al. Interaction of lithium with 5-HT1B receptors in depressed unipolar patients treated with clomipramine and lithium versus clomipramine and placebo: preliminary results. Psychiatry Res 2002; 111: 117-24